Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Brainever |
| Country | France |
| Start Date | Nov 01, 2022 |
| End Date | Oct 31, 2024 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190105256 |
With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases.
At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs).
Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration.
When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases.
In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinsons Disease (PD).
Brainever
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant